Evidence map›Paper›PMID 36109543›Full record

ArticleScientific reports2022

Development of process analytical tools for rapid monitoring of live virus vaccines in manufacturing.

Sijia Yi, Reilly McCracken, Joseph Davide, Daniel Ryan Salovich, Travis Whitmer, Aditya Bhat, Josef Vlasak, Sha Ha, Darrell Sehlin, Joseph Califano and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sijia YiVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Reilly McCrackenVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Joseph DavideVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Daniel Ryan SalovichVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Travis WhitmerVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Aditya BhatAber Instruments Inc, Alexandria, VA, USA.
Josef VlasakVaccines Analytical Development, Merck & Co., Inc., West Point, PA, USA.
Sha HaVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Darrell SehlinVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Joseph CalifanoVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Kristin PloegerVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA.
Malini MukherjeeVaccines Process Development and Commercialization, Merck & Co., Inc., 770 Sumneytown Pike, WP 42-3, West Point, PA, 19486, USA. malini.mukherjee@merck.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the development of end-to-end large-scale live virus vaccine (LVV) manufacturing, process analytical technology (PAT) tools enable timely monitoring of critical process parameters (CPP) and significantly guide process development and characterization. In a commercial setting, these very same tools can enable real time monitoring of CPPs on the shop floor and inform harvest decisions, predict peak potency, and serve as surrogates for release potency assays. Here we introduce the development of four advanced PAT tools for upstream and downstream process monitoring in LVV manufacturing. The first tool explores the application of capacitance probes for real time monitoring of viable cell density in bioreactors. The second tool utilizes high content imaging to determine optimum time of infection in a microcarrier process. The third tool uses flow virometry (or nanoscale flow cytometry) to monitor total virus particle counts across upstream and downstream process steps and establishes a robust correlation to virus potency. The fourth and final tool explores the use of nucleic acid dye staining to discriminate between "good" and "damaged" virus particles and uses this strategy to also monitor virus aggregates generated sometimes during downstream processing. Collectively, these tools provide a comprehensive monitoring toolbox and represent a significantly enhanced control strategy for the manufacturing of LVVs.

Indexed as

Nucleic AcidsVaccinesBioreactorsNucleic AcidsVaccines

Identifiers

PMID36109543
PMCPMC9476422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.